These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27029823)

  • 61. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
    Lincoln J; Stewart ME; Preskorn SH
    J Psychiatr Pract; 2010 Mar; 16(2):103-14. PubMed ID: 20511734
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
    Heath EI; Chiorean EG; Sweeney CJ; Hodge JP; Lager JJ; Forman K; Malburg L; Arumugham T; Dar MM; Suttle AB; Gainer SD; LoRusso P
    Clin Pharmacol Ther; 2010 Dec; 88(6):818-23. PubMed ID: 20980999
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
    Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
    Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Systemic exposure to rosiglitazone is unaltered by food.
    Freed MI; Allen A; Jorkasky DK; DiCicco RA
    Eur J Clin Pharmacol; 1999 Mar; 55(1):53-6. PubMed ID: 10206085
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effect of food on the absorption of oral ziprasidone.
    Miceli JJ; Glue P; Alderman J; Wilner K
    Psychopharmacol Bull; 2007; 40(3):58-68. PubMed ID: 18007569
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
    Gupta N; Hanley MJ; Venkatakrishnan K; Wang B; Sharma S; Bessudo A; Hui AM; Nemunaitis J
    J Clin Pharmacol; 2016 Oct; 56(10):1288-95. PubMed ID: 26872892
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.
    Xin Y; Shao L; Maltzman J; Stefanidis D; Hemenway J; Tarnowski T; Deng W; Silverman JA
    Clin Pharmacol Drug Dev; 2018 Mar; 7(3):277-286. PubMed ID: 29024542
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.
    Cox DS; Papadopoulos K; Fang L; Bauman J; LoRusso P; Tolcher A; Patnaik A; Pendry C; Orford K; Ouellet D
    J Clin Pharmacol; 2013 Sep; 53(9):946-54. PubMed ID: 23893461
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative effect of different types of food on the bioavailability of cefaclor extended release tablet.
    Khan BA; Ahmed T; Karim S; Monif T; Saha N; Sharma PL
    Eur J Drug Metab Pharmacokinet; 2004; 29(2):125-32. PubMed ID: 15230341
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of dietary fat content in meals on pharmacokinetics of quazepam.
    Yasui-Furukori N; Kondo T; Takahata T; Mihara K; Ono S; Kaneko S; Tateishi T
    J Clin Pharmacol; 2002 Dec; 42(12):1335-40. PubMed ID: 12463728
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin.
    Sahasrabudhe V; Fediuk DJ; Matschke K; Shi H; Liang Y; Hickman A; Bass A; Terra SG; Zhou S; Krishna R; Dawra VK
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):619-627. PubMed ID: 30427588
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Venetoclax: First Global Approval.
    Deeks ED
    Drugs; 2016 Jun; 76(9):979-87. PubMed ID: 27260335
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.
    Sauron R; Wilkins M; Jessent V; Dubois A; Maillot C; Weil A
    Int J Clin Pharmacol Ther; 2006 Feb; 44(2):64-70. PubMed ID: 16502765
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
    Weber EJ; Younis IR; Wang L; Xiao D; Barchuk WT; Othman AA
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):677-687. PubMed ID: 38346861
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 78. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers.
    Vachharajani NN; Shyu WC; Mantha S; Park JS; Greene DS; Barbhaiya RH
    J Clin Pharmacol; 1998 May; 38(5):433-6. PubMed ID: 9602956
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent.
    Žigart N; Časar Z
    Expert Opin Ther Pat; 2019 Jul; 29(7):487-496. PubMed ID: 31154862
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate.
    Heinig R; Sachse R
    Int J Clin Pharmacol Ther; 1999 Sep; 37(9):456-64. PubMed ID: 10507245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.